JPMorgan just turned 50% of its defense equity war chest into deals — the deposit-taker is now the Pentagon's banker of first resort

JPMorgan's SRI was launched on Oct 13, 2025, with a $1.5 trillion, 10-year facilitation target — a combination of advisory, lending, and up to $10B in direct equity from the bank's own books. Inside twelve months the equity line has already gone halfway: $5B deployed across defense tech, autonomy, hypersonics, and critical minerals. The remaining $5B is committed but not yet publicly itemized. The bank is on a glide path that compresses the ten-year equity budget into roughly the first three years.

The shift matters because U.S. deposit-taking banks have largely stayed out of defense venture and growth equity since the 1980s-era ESG pullback. Investment banks — Goldman Sachs above all — have dominated M&A advisory in defense, but their capital has stayed on the fee side. By stepping into equity, JPMorgan is competing not only with Goldman for advisory dollars but with a16z, Carlyle, and the sovereign-LP complex for ownership stakes. That re-prices the cost of capital across the entire defense industrial base.

Three publicly identifiable equity checks from the $5B are enough to sketch the strategy. Each one targets a different chokepoint the Pentagon has flagged: critical minerals, autonomous combat software, and low-cost hypersonic strike.

The pattern is unmistakable. Critical minerals (antimony via Perpetua Resources, rare earths via MP Materials) anchor the upstream. Autonomy and hypersonics (Shield AI, Castelion) anchor the downstream. The bank is not chasing the legacy primes — it is funding the new entrants that the primes will have to acquire or partner with over the next five years.

The first SRI check, Perpetua Resources, is the cleanest expression of the policy lever. Stibnite is the only U.S. project permitted to produce antimony at scale. China refines roughly 91% of the world's rare earths and antimony; the Pentagon's 10-year offtake at MP Materials and its $150M loan are explicit industrial-base policy. JPMorgan followed with the only direct equity deal it has disclosed in a U.S. critical-minerals miner — the implication is that JPM is now picking which North American critical-mineral projects get a sovereign-style validation.

The legacy primes — Lockheed Martin, Northrop Grumman, RTX, General Dynamics, L3Harris, Huntington Ingalls — are not equity targets of the SRI. They are its customers. Their FY2026 backlog expansion was already underway when SRI launched: NOC's backlog rose 17% YoY to $104.7B; RTX raised its 2026 sales guide to $95–96B from $92.5–93.5B; the Pentagon's shipbuilding request for FY27 hit $65.8B, the highest since 1962, with $1.5B earmarked for the maritime industrial base. SRI's $230B in first-year facilitated financing is the credit spigot behind that backlog.

The transmission is not equity-led. It is balance-sheet-led. JPMorgan's SRI group bundles direct equity (the public-facing 50% of $10B) with traditional revolving credit, term loans, and supply-chain inventory finance for the Tier-1 primes. A defense tech company co-led by SRI becomes a future supplier to the primes, and the primes become overnight buyers of the credit products JPM offers them.

The underappreciated angle is fee economics. By co-leading Shield AI's $2B round and Castelion's $1.05B round, JPMorgan is positioning itself as the natural sell-side banker when these companies IPO or are acquired by Lockheed Martin, Northrop Grumman, RTX, or General Dynamics. Defense-tech M&A is accelerating: Anduril at $61B, Saronic at $9.25B, Castelion at $13B — these are pre-IPO companies that will need M&A or IPO banks within three years.

Goldman Sachs — the historical incumbent in defense advisory — published a research note in August 2026 titled \"Beyond the Horizon\" estimating the defense-and-space market could reach $5T. That is the pie JPMorgan is now carving out by entering the equity layer. Even a 10% share of defense-tech IPO/MA advisory across 2027–2030 would dwarf the $5B equity deployment in fees.

Near-term the equity story is execution. The bank has telegraphed that the next leg of SRI will focus on industrial capacity, supply chains, and resilience — language from Jay Horine, head of the SRI. The two largest immediate beneficiaries are the listed critical-minerals names: MP Materials and Perpetua Resources. Their pipeline of capacity projects (MP's Texas magnet facility, Perpetua's Stibnite commissioning) is the type of capex SRI capital can accelerate.

Two to three years out, the bigger question is whether SRI reshapes the cost of capital for U.S. defense supply. Today, defense tech startups can raise from venture, from the Pentagon's Office of Strategic Capital (OSC), and from a handful of crossover funds. Adding a $10B-equity deposit bank to that mix changes the marginal LP. It also tightens the link between private capital and industrial-policy outcomes: if the Pentagon publishes a National Defense Industrial Strategy that names antimony, hypersonics, or undersea autonomy, JPM's SRI has both the motivation and the balance sheet to be the first mover.

The Oct 19, 2026 update is not a one-day story. It is the moment Wall Street's largest balance sheet publicly acknowledged that the U.S. defense industrial base is a private-asset class — and that the bank, not the sovereign wealth fund or the crossover fund, is going to set its price. JPMorgan has used $5B of equity and $230B of credit in twelve months to do three things: validate critical-minerals policy (Perpetua Resources, MP Materials), bankroll the autonomy and hypersonic gap (Shield AI, Castelion), and pre-position itself as the IPO/M&A advisor when these companies mature.

For investors, the actionable edge is not in JPMorgan itself — the SRI is too small relative to its $301.9B TTM revenue to move the stock on its own. It is in the listed names across the supply chain the bank is underwriting: defense primes with expanding backlogs (Lockheed Martin, Northrop Grumman, RTX), the critical-minerals enablers (MP Materials, Perpetua Resources), and the bellwether bank competitor (Goldman Sachs) that has to respond. Fact: $5B deployed and three named deals in twelve months. Inference: the next 12 months will bring at least two more large checks and one IPO candidate. Speculation: a Q1 2027 administration policy re-set could compress critical-minerals multiples without touching the prime backlog thesis.